Zytiga FDA Approval History
FDA Approved: Yes (First approved April 28, 2011)
Brand name: Zytiga
Generic name: abiraterone
Dosage form: Tablets
Company: Centocor Ortho Biotech Inc.
Treatment for: Prostate Cancer
Zytiga (abiraterone acetate) is a CYP17 inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.
Development Timeline for Zytiga
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.